rhinitis%20-%20nonallergic
RHINITIS - NONALLERGIC
Nonallergic rhinitis is the inflammation of the nasal lining membranes without any immunoglobulin E mediation, as documented by allergen skin testing.
Major signs and symptoms include nasal itching, watery rhinorrhea, nasal obstruction/congestion, sneezing and postnasal drainage.
Symptoms can reverse spontaneously with or without treatment.

Principles of Therapy

  • If possible, treatment should be aimed at the underlying causative physiology of nonallergic rhinitis
  • No single medication or individual medication class can treat the entire spectrum of symptoms
  • Treatment response may be less satisfactory than in allergic rhinitis

Pharmacotherapy

Anticholinergics (Nasal)
  • Block the muscarinic receptors of the seromucinous glands
  • Ideal for patients who present only w/ rhinorrhea
  • Have no activity against sneezing, itching or nasal congestion
Antihistamines (Nasal)
  • H1-receptor antagonists reduce nasal itching, sneezing & rhinorrhea, but are less effective for nasal obstruction
  • May have limited benefit in nonallergic rhinitis unless symptoms result from histamine release
  • Oral antihistamines may be used as adjunctive therapy in some patients; topical antihistamines have shown better efficacy for non-allergic rhinitis
Corticosteroids (Nasal)
  • Reduce airway hyperresponsiveness, amount & activity of inflammatory mediators, & allow relaxation of smooth muscle
  • Decrease sneezing, pruritus, rhinorrhea & nasal obstruction
  • Recommended as 1st-line treatment for symptoms of nonallergic rhinitis
  • Onset of action is relatively slow (6-12 hours), w/ maximum efficacy developing after 2-3 weeks
  • Better response is achieved w/ continuous use rather than w/ as-required use
  • Patient should be maintained on the lowest dose which achieves symptom control
  • Aqueous preparations are preferred because they are less irritating to the nasal mucosa
  • Intranasal corticosteroids w/ low bioavailability is suggested since it has been shown to have no effect on growth
Decongestants
  • Provoke vasoconstriction by acting on adrenergic receptors, thus relieving swelling of the nasal mucosa
Nasal Decongestants
  • Very effective in relieving nasal obstruction
  • Because of the risk of rebound vasodilation (rhinitis medicamentosa) & atrophic rhinitis w/ prolonged use, their use should be limited to <10 days
Oral Decongestants
  • Have weaker effect on nasal obstruction than topical preparations, but do not cause rebound vasodilatation
  • May be given to patients w/ nasal congestion unresponsive to intranasal corticosteroids, Azelastine, or a combination of both

Non-Pharmacological Therapy

Nasal Saline Irrigation
  • Nasal lavage or saline spray is useful for postnasal drainage symptoms
  • Cleanses nasal mucosa when used before intranasal corticosteroids or Azelastine
Other Investigational Agents
  • Some studies show benefit of Capsaicin, Ribomunyl & Silver nitrate for rhinitis symptoms
    • Capsaicin & Silver nitrate may be used for vasomotor rhinitis & Ribomunyl for infectious rhinitis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Audrey Abella, 16 Feb 2017
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) during acute respiratory infection episodes may increase the risk of acute myocardial infarction (MI), a recent study from Taiwan shows.
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Pearl Toh, 01 Mar 2016
Asthma development in young children may be associated with paracetamol exposure during maternal pregnancy or infancy, a new study on the MoBa* cohort showed.
Rachel Soon, 01 Jun 2017

Pirfenidone, an oral antifibrotic and anti-inflammatory agent, is now indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in Malaysia.